These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
180 related articles for article (PubMed ID: 31497753)
1. Covalent Poly(lactic acid) Nanoparticles for the Sustained Delivery of Naloxone. Kassick AJ; Allen HN; Yerneni SS; Pary F; Kovaliov M; Cheng C; Pravetoni M; Tomycz ND; Whiting DM; Nelson TL; Feasel M; Campbell PG; Kolber B; Averick S ACS Appl Bio Mater; 2019 Aug; 2(8):3418-3428. PubMed ID: 31497753 [TBL] [Abstract][Full Text] [Related]
3. Covalently Loaded Naloxone Nanoparticles as a Long-Acting Medical Countermeasure to Opioid Poisoning. Kassick AJ; Wu M; Luengas D; Ebqa'ai M; Tharika Nirmani LP; Tomycz N; Nelson TL; Pravetoni M; Raleigh MD; Averick S ACS Pharmacol Transl Sci; 2021 Oct; 4(5):1654-1664. PubMed ID: 34661081 [TBL] [Abstract][Full Text] [Related]
4. Novel Oral Nanoparticle Formulation of Sustained Release Naloxone with Mild Withdrawal Symptoms in Mice. Madison CA; Arora M; Kumar MNVR; Eitan S ACS Chem Neurosci; 2020 Jul; 11(13):1955-1964. PubMed ID: 32491828 [TBL] [Abstract][Full Text] [Related]
5. Real-world study of multiple naloxone administration for opioid overdose reversal among bystanders. Abdelal R; Raja Banerjee A; Carlberg-Racich S; Darwaza N; Ito D; Shoaff J; Epstein J Harm Reduct J; 2022 May; 19(1):49. PubMed ID: 35596213 [TBL] [Abstract][Full Text] [Related]
6. Engineering Quick- and Long-acting Naloxone Delivery Systems for Treating Opioid Overdose. Sharifi F; Meqbil YJ; Otte A; Gutridge AM; Blaine AT; van Rijn RM; Park K Pharm Res; 2021 Jul; 38(7):1221-1234. PubMed ID: 34114163 [TBL] [Abstract][Full Text] [Related]
7. Intranasal delivery of Naloxone-loaded solid lipid nanoparticles as a promising simple and non-invasive approach for the management of opioid overdose. Hasan N; Imran M; Kesharwani P; Khanna K; Karwasra R; Sharma N; Rawat S; Sharma D; Ahmad FJ; Jain GK; Bhatnagar A; Talegaonkar S Int J Pharm; 2021 Apr; 599():120428. PubMed ID: 33662465 [TBL] [Abstract][Full Text] [Related]
8. Pharmacological Profiling of Antifentanyl Monoclonal Antibodies in Combination with Naloxone in Pre- and Postexposure Models of Fentanyl Toxicity. Baehr CA; Wu MM; Pandit SG; Arias-Umana J; AuCoin D; Pravetoni M J Pharmacol Exp Ther; 2022 May; 381(2):129-136. PubMed ID: 35153198 [TBL] [Abstract][Full Text] [Related]
9. On-Demand Opioid Effect Reversal with an Injectable Light-Triggered Polymer-Naloxone Conjugate. Zhang W; Wang D; Ostertag-Hill CA; Han Y; Li X; Zheng Y; Lu B; Kohane DS Nano Lett; 2023 Nov; 23(22):10545-10553. PubMed ID: 37937844 [TBL] [Abstract][Full Text] [Related]
10. Estimating naloxone need in the USA across fentanyl, heroin, and prescription opioid epidemics: a modelling study. Irvine MA; Oller D; Boggis J; Bishop B; Coombs D; Wheeler E; Doe-Simkins M; Walley AY; Marshall BDL; Bratberg J; Green TC Lancet Public Health; 2022 Mar; 7(3):e210-e218. PubMed ID: 35151372 [TBL] [Abstract][Full Text] [Related]
11. Evaluating the rate of reversal of fentanyl-induced respiratory depression using a novel long-acting naloxone nanoparticle, cNLX-NP. Averick SE; Kassick AJ; Song D; Zhang B; Vigliaturo J; Luengas D; Silva-Ortiz P; Pravetoni M; Raleigh MD Front Psychiatry; 2024; 15():1366186. PubMed ID: 38550534 [TBL] [Abstract][Full Text] [Related]
12. Antinociceptive effects of morphine and naloxone in mu-opioid receptor knockout mice transfected with the MORS196A gene. Chen SL; Ma HI; Han JM; Lu RB; Tao PL; Law PY; Loh HH J Biomed Sci; 2010 Apr; 17(1):28. PubMed ID: 20403204 [TBL] [Abstract][Full Text] [Related]
13. The Effect of Naloxone Access Laws on Fatal Synthetic Opioid Overdose Fatality Rates. Tabatabai M; Cooper RL; Wilus DM; Edgerton RD; Ramesh A; MacMaster SA; Patel PN; Singh KP J Prim Care Community Health; 2023; 14():21501319221147246. PubMed ID: 36625264 [TBL] [Abstract][Full Text] [Related]